



## **Guerbet launches Contrast&Care<sup>®</sup> 2.0, the new version of its digital solution for managing the injection of contrast media for medical imaging centers**

Contrast&Care<sup>®</sup> 2.0 will be presented at the RSNA (Radiological Society North America) Congress in Chicago, to be held from November 25<sup>th</sup> to 30<sup>th</sup>, 2018

**Villepinte (France), November 21<sup>st</sup>, 2018 (8:00 CET)** – Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, today announced the worldwide launch of its new version of Contrast&Care<sup>®</sup>, a digital contrast media injection management solution for medical imaging centers, available in 14 languages.

Contrast&Care<sup>®</sup> 2.0 is a good demonstration of Guerbet's commitment to strengthening its digital strategy, with the aim of improving the productivity of healthcare professionals and patient safety.

Offering “smart connectivity” and a new “smart reader” feature, version 2.0 connects with all CT, Cath Lab and MRI injectors in the current Guerbet range (OptiOne<sup>®</sup>, OptiVantage<sup>®</sup>, OptiStar<sup>®</sup> Elite, Illumena<sup>®</sup> Neo, FlowSens<sup>®</sup>) and allows users to scan and read data on mobile devices in addition to computers. These new functionalities have been added in response to requests from radiology professionals.

Contrast&Care<sup>®</sup> 2.0 will also benefit from a cloud support service approved for hosting healthcare data, in order to meet customers' needs more rapidly and safely (installation, updates and maintenance).

Contrast&Care<sup>®</sup> is an integrated IT solution launched in November 2017 that groups together all data relating to examinations involving injections (contrast agent, injection protocol, patient data, etc.) and interfaces with the information systems used in radiology, including the RIS (Radiology Information System), the PACS (Picture Archiving and Communication System) and EMR (Electronic Medical Records). This solution improves efficiency and traceability and simplifies decision-making processes at imaging centers.

The information generated by injectors is sent automatically to Contrast&Care<sup>®</sup> following each examination.

## Press release

Users can view the history of a patient's data, the examinations involving injections and the doses of contrast media administered. Contrast&Care<sup>®</sup> also offers the optional ability to review protocols, create libraries of protocols and visualize statistics and trends on injection activity and use of contrast agents.

*“We are delighted to be able to present this version 2.0 of Contrast&Care<sup>®</sup> as a demonstration of our commitment to further improve mobility, safety and productivity, in order to make it easier for healthcare professionals to take decisions. It is in line with our 5-year GEAR 2023 strategic plan aimed at shaping the future of medical imaging,”* said David Hale, Chief Commercial Officer, Diagnostic Imaging.

The global commercial launch of Contrast&Care<sup>®</sup> 2.0 will begin during RSNA congress where Guerbet specialists will give interactive demonstrations.

### About Contrast&Care<sup>®</sup>

---

Contrast&Care<sup>®</sup> is a class I/CE medical device designed to be used by healthcare professionals only. It is a contrast agent injection management solution that enables imaging centers to collect, archive, examine and share injection data, including data on contrast media, adverse events, injector activity, information on the estimated glomerular filtration rate (eGFR) and other risk factors before an exam.

Contrast&Care<sup>®</sup> is available in German, UK and US English, Traditional and Simplified Chinese, Korean, Spanish, French, Dutch, Italian, Polish, Brazilian and Portugal Portuguese and Thai.

For more information, please refer to the information leaflet and instructions for use. Contrast&Care<sup>®</sup> is manufactured by Medex, a subsidiary of the Guerbet Group (Saint-Priest France).

### About Guerbet

---

Guerbet is a pioneer in the contrast-agent field, with more than 90 years' experience, and is a leader in medical imaging worldwide. It offers a comprehensive range of pharmaceutical products, medical devices and services for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients. With 8% of revenue dedicated to R&D and more than 200 employees distributed amongst its four centers in France, Israel and the United States, Guerbet is a substantial investor in research and innovation. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €807 million in revenue in 2017.

For more information about Guerbet, please visit [www.guerbet.com](http://www.guerbet.com).

### Media Relations

---

#### **Guerbet Global**

**Alize RP**

Caroline Carmagnol and Tatiana Vieira

1+33 (0)1 44 54 36 65 / +33 (0)6 31 19 76 20

[guerbet@alizerp.com](mailto:guerbet@alizerp.com)